Trials / Completed
CompletedNCT07314320
A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men
A Phase 1, Open-Label, Single-Dose Trial to Evaluate the Mass Balance and Pharmacokinetics of [14C]-OPC-167832 Administered Orally in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of \[14C\]-OPC-167832 in healthy male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-OPC-167832 | Oral suspension |
Timeline
- Start date
- 2023-11-20
- Primary completion
- 2023-12-27
- Completion
- 2023-12-27
- First posted
- 2026-01-02
- Last updated
- 2026-01-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07314320. Inclusion in this directory is not an endorsement.